| 王 磊,胡丰庆,孟礼飞,王明松,李国庆,梅 举.肺鳞癌和肺腺癌FGFR融合基因的临床意义[J].现代生物医学进展英文版,2018,(5):867-871. |
| 肺鳞癌和肺腺癌FGFR融合基因的临床意义 |
| Clinical Significances of FGFR Fusion for the Lung Squamous Cell Carcinoma and Adenocarcinoma |
| Received:July 19, 2017 Revised:August 11, 2017 |
| DOI：10.13241/j.cnki.pmb.2018.05.014 |
| 中文关键词: 非小细胞肺癌 FGFR 融合基因 |
| 英文关键词: Non-small cell lung cancer FGFR Fusion |
| 基金项目:上海市青年科技英才扬帆计划项目(15YF1407800)；国家自然科学基金项目（81602418） |
|
| Hits: 597 |
| Download times: 439 |
| 中文摘要: |
| 摘要 目的：探讨肺鳞癌和肺腺癌FGFR融合基因状态及其临床病理意义。方法：采用逆转录-聚合酶链反应(RT-PCR)和直接测序的方法检测2011年1月到2013年12月在我科行手术切除治疗的肺鳞癌和肺腺癌样本的FGFR融合基因，分析患者的临床病理学资料如性别、年龄、吸烟状况、肿瘤大小、病理类型、分化程度，并与对应样本的EGFR、KRAS、HER2、BRAF等常见驱动基因突变进行比较研究。结果：入组患者共512例，包括119例鳞癌和393例腺癌。FGFR融合基因的发生频率为1.2%(6/512)，该分子亚型好发于病理证实为肺鳞癌(66.7%，p=0.029)、直径大于3厘米(83.3%，p=0.029)的男性(83.3%，p=0.028)吸烟患者(83.3%，p=0.038)。腺癌融合基因样本均含有实体病理亚型。结论：FGFR融合基因是肺鳞癌和肺腺癌的重要分子亚型，可能起驱动基因作用，具有该特征的肺癌亚群患者很可能将受益于FGFR靶基因研究与靶向治疗。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the FGFR fusion and its clinical significance in the lung squamous cell carcinoma and adenocar- cinoma. Methods: The retrospective series of NSCLCs were investigated for FGFR fusion by reverse transcriptase polymerase chain reac- tion (RT-PCR) followed by direct sequencing from January 2011 to December 2013. All patients were also analyzed for EGFR, KRAS, HER2 and BRAF mutations. Results: 512 cases were enrolled to our study including 119 squamous cell carcinoma and 393 adenocarci- noma.We found that 1.2% of the cases harbored FGFR fusion. Compared to the FGFR-negative group, patients with FGFR fusion were more likely to be male(p=0.028) smokers(p=0.038), significantly associated with squamous cell carcinoma(p=0.029), more likely to have large tumor(>3 cm) (p=0.029). Moreover, There were no significant differences in RFS or OS between patients with and without FGFR fusions. Conclusion: FGFR fusions identified a distinct subset of NSCLC with a higher prevalence among smokers with squamous cell carcinoma and relative larger tumor (>3 cm). This part of our study provided a clinical reference in targeted therapy screening with non-small cell lung cancer and was helpful for anticipating the prognosis in Chinese NSCLC patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
